Sublocade
Pain, Opioid-Related Disorders, Pain
Treatment
2 FDA approvals
0 Active Studies for Sublocade
Treatment for
Pain
What is Sublocade
Buprenorphine
The Generic name of this drug
Treatment Summary
Buprenorphine is a medication used to treat severe pain and opioid addiction. It is sold under the brand name Suboxone and contains a combination of buprenorphine and naloxone, with the latter helping to reduce the potential for abuse. Buprenorphine is unique in that it binds to opioid receptors slowly, providing relief of pain or withdrawal symptoms for up to 24-36 hours. It also has a “ceiling effect”, meaning that once a certain dose is reached, further increases in dosage do not increase the effects. Buprenorphine is commonly used in opioid agonist
Buprenex
is the brand name
Sublocade Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Buprenex
Buprenorphine
1985
261
Approved as Treatment by the FDA
Buprenorphine, commonly known as Buprenex, is approved by the FDA for 2 uses which include Opioid Dependence and Opioid-Related Disorders .
Opioid Dependence
Used to treat Opioid Dependence in combination with Naloxone
Opioid-Related Disorders
Used to treat Opioid Dependence in combination with Naloxone
Effectiveness
How Sublocade Affects Patients
Buprenorphine is a drug that interacts with the opioid mu-receptor in the brain and spinal cord, reducing pain and making people feel sleepy. It can also cause physical dependence and withdrawal symptoms if stopped suddenly. Taking it too much or too quickly can cause life-threatening respiratory depression and death. It can also make the bowels slow down, cause changes in hormones, and lead to adrenal insufficiency. Buprenorphine is not recommended for those with severe or moderate liver problems, and should be used with caution in those with head injuries or other conditions that can raise cerebrospinal fluid pressure. It
How Sublocade works in the body
Buprenorphine is a drug that is used to treat opioid addiction. It works by binding to the mu-opioid receptor, but not activating it to the same degree as more potent opioids, like heroin or oxycodone. This results in a slow onset of action and a “ceiling effect”, which means that there is a maximum amount of the drug that can be taken before the effects stop increasing. This can be beneficial because it reduces the risk of overdose and side effects, but also makes it less likely to cause drug-seeking behaviors. However, if buprenorph
When to interrupt dosage
The proposed dosage of Sublocade is contingent upon the determined condition, such as Pain, Pain and Opioid Dependence. The amount also differs depending on the method of delivery (e.g. Tablet - Oral or Sublingual) depicted in the table below.
Condition
Dosage
Administration
Pain
0.324 mg/mL, , 0.3 mg/mL, 8.0 mg, 0.01 mg/hour, 0.02 mg/hour, 0.005 mg/hour, 2.0 mg, 80.0 mg, 16.0 mg, 0.075 mg, 0.15 mg, 0.3 mg, 0.45 mg, 0.6 mg, 0.75 mg, 0.9 mg, 0.0075 mg/hour, 0.015 mg/hour, 12.0 mg, 4.0 mg, 1.4 mg, 11.4 mg, 2.9 mg, 5.7 mg, 8.6 mg, 0.7 mg, 4.2 mg, 2.1 mg, 6.3 mg, 0.2 mg, 300.0 mg, 100.0 mg, 0.0025 mg/hour, 74.2 mg, 96.0 mg, 24.0 mg, 128.0 mg, 64.0 mg, 32.0 mg, 300.0 mg/mL, 1000.0 mg/mL, 7.5 mg/hour, 15.0 mg/hour, 20.0 mg/hour, 5.0 mg/hour, 10.0 mg/hour
, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Sublingual, Tablet, Tablet - Sublingual, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet - Oral, Film, soluble, Film, soluble - Sublingual, Subcutaneous, Implant, Implant - Subcutaneous, Buccal, Film, Film - Buccal, Injection - Intramuscular; Intravenous, Injection, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Patch, Patch - Transdermal, Film, soluble - Buccal, Pill - Sublingual, Pill, Solution - Subcutaneous, Solution, Film, soluble - Buccal; Sublingual, Buccal; Sublingual, Film - Buccal; Sublingual, Solution, gel forming, extended release, Solution, gel forming, extended release - Subcutaneous
Opioid-Related Disorders
0.324 mg/mL, , 0.3 mg/mL, 8.0 mg, 0.01 mg/hour, 0.02 mg/hour, 0.005 mg/hour, 2.0 mg, 80.0 mg, 16.0 mg, 0.075 mg, 0.15 mg, 0.3 mg, 0.45 mg, 0.6 mg, 0.75 mg, 0.9 mg, 0.0075 mg/hour, 0.015 mg/hour, 12.0 mg, 4.0 mg, 1.4 mg, 11.4 mg, 2.9 mg, 5.7 mg, 8.6 mg, 0.7 mg, 4.2 mg, 2.1 mg, 6.3 mg, 0.2 mg, 300.0 mg, 100.0 mg, 0.0025 mg/hour, 74.2 mg, 96.0 mg, 24.0 mg, 128.0 mg, 64.0 mg, 32.0 mg, 300.0 mg/mL, 1000.0 mg/mL, 7.5 mg/hour, 15.0 mg/hour, 20.0 mg/hour, 5.0 mg/hour, 10.0 mg/hour
, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Sublingual, Tablet, Tablet - Sublingual, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet - Oral, Film, soluble, Film, soluble - Sublingual, Subcutaneous, Implant, Implant - Subcutaneous, Buccal, Film, Film - Buccal, Injection - Intramuscular; Intravenous, Injection, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Patch, Patch - Transdermal, Film, soluble - Buccal, Pill - Sublingual, Pill, Solution - Subcutaneous, Solution, Film, soluble - Buccal; Sublingual, Buccal; Sublingual, Film - Buccal; Sublingual, Solution, gel forming, extended release, Solution, gel forming, extended release - Subcutaneous
Pain
0.324 mg/mL, , 0.3 mg/mL, 8.0 mg, 0.01 mg/hour, 0.02 mg/hour, 0.005 mg/hour, 2.0 mg, 80.0 mg, 16.0 mg, 0.075 mg, 0.15 mg, 0.3 mg, 0.45 mg, 0.6 mg, 0.75 mg, 0.9 mg, 0.0075 mg/hour, 0.015 mg/hour, 12.0 mg, 4.0 mg, 1.4 mg, 11.4 mg, 2.9 mg, 5.7 mg, 8.6 mg, 0.7 mg, 4.2 mg, 2.1 mg, 6.3 mg, 0.2 mg, 300.0 mg, 100.0 mg, 0.0025 mg/hour, 74.2 mg, 96.0 mg, 24.0 mg, 128.0 mg, 64.0 mg, 32.0 mg, 300.0 mg/mL, 1000.0 mg/mL, 7.5 mg/hour, 15.0 mg/hour, 20.0 mg/hour, 5.0 mg/hour, 10.0 mg/hour
, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Sublingual, Tablet, Tablet - Sublingual, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet - Oral, Film, soluble, Film, soluble - Sublingual, Subcutaneous, Implant, Implant - Subcutaneous, Buccal, Film, Film - Buccal, Injection - Intramuscular; Intravenous, Injection, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Patch, Patch - Transdermal, Film, soluble - Buccal, Pill - Sublingual, Pill, Solution - Subcutaneous, Solution, Film, soluble - Buccal; Sublingual, Buccal; Sublingual, Film - Buccal; Sublingual, Solution, gel forming, extended release, Solution, gel forming, extended release - Subcutaneous
Warnings
Sublocade Contraindications
Condition
Risk Level
Notes
Alcohol Withdrawal Delirium
Do Not Combine
Asthma
Do Not Combine
Severe Hepatic Impairment
Do Not Combine
suspected gastrointestinal obstruction
Do Not Combine
Pulse Frequency
Do Not Combine
Asthma
Do Not Combine
Gastrointestinal obstruction
Do Not Combine
Head
Do Not Combine
ethanol
Do Not Combine
Stomatitis
Do Not Combine
Abdomen
Do Not Combine
severe CNS depression
Do Not Combine
opioid naive
Do Not Combine
Myasthenia Gravis
Do Not Combine
Epilepsy
Do Not Combine
Hypocalcemia
Do Not Combine
Hypokalemia
Do Not Combine
Hypomagnesemia
Do Not Combine
Mental Depression
Do Not Combine
Cerebrospinal Fluid
Do Not Combine
Long QT Syndrome
Do Not Combine
There are 20 known major drug interactions with Sublocade.
Common Sublocade Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Buprenorphine.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Buprenorphine.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Buprenorphine.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Buprenorphine.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Buprenorphine.
Sublocade Toxicity & Overdose Risk
Signs of a fentanyl overdose include small pupils, drowsiness, low blood pressure, slower breathing, and in extreme cases, death.
Sublocade Novel Uses: Which Conditions Have a Clinical Trial Featuring Sublocade?
21 active clinical trials are currently investigating the potential of Sublocade to address Opioid Dependence, Pain and Painful Disorders.
Condition
Clinical Trials
Trial Phases
Pain
0 Actively Recruiting
Pain
0 Actively Recruiting
Opioid-Related Disorders
0 Actively Recruiting
Sublocade Reviews: What are patients saying about Sublocade?
5
Patient Review
10/21/2022
Sublocade for Narcotic Addiction
4.7
Patient Review
3/21/2022
Sublocade for Narcotic Addiction
4.7
Patient Review
5/12/2022
Sublocade for Narcotic Addiction
4.7
Patient Review
7/10/2022
Sublocade for Narcotic Addiction
4.3
Patient Review
7/8/2022
Sublocade for Narcotic Addiction
1
Patient Review
5/2/2022
Sublocade for Narcotic Addiction
Patient Q&A Section about sublocade
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How long does the Sublocade shot last?
"Sublocade is an injection that you receive once a month. A single injection will last between 28 to 30 days, according to the package insert. You must wait a minimum of 26 days in between Sublocade doses."
Answered by AI
What is Sublocade injection used for?
"SUBLOCADE is indicated as a treatment for moderate to severe opioid use disorder in patients who have already started treatment with a product that contains buprenorphine, and have had their dosage adjusted for a minimum of 7 days."
Answered by AI
Is Suboxone the same as Sublocade?
"Sublocade is a monthly injection containing only buprenorphine, while Suboxone is a daily film containing both buprenorphine and naloxone. Naloxone helps protect people from an inadvertent opioid overdose."
Answered by AI